163 related articles for article (PubMed ID: 36314172)
1. Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
Cho YK; Kim JH; Kim HS; Kim TO; Oh JH; Choi SC; Moon JS; Lee SK; Jung SW; Kim SS; Jung HK; Lee SP; Cheon GJ; Park MI; Jung HY; Ko KH; Sung IK; Lee SH; Lee JY; Lee ST; Rhee PL; Kim N; Hong SJ; Kim HJ; Kim GH; Lee KJ; Kim SK; Shin WG; Lee OY
Aliment Pharmacol Ther; 2023 Jan; 57(1):72-80. PubMed ID: 36314172
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK; Choi MG; Choi SC; Lee KM; Kim TO; Park SH; Moon JS; Lim YJ; Kang DH; Cheon GJ; Baik GH; Kim KO; Cho KB; Jang JS; Park JJ; Son BK; Jung HK; Kim BW; Kim SK; Lee ST; Cha JM; Kim AR; Kim EJ; Park HW; Song GS
Aliment Pharmacol Ther; 2020 Sep; 52(5):789-797. PubMed ID: 32701188
[TBL] [Abstract][Full Text] [Related]
4. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
5. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
7. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Chen S; Liu D; Chen H; Liao A; Li F; Liu C; Li X; Li S; Zhang Y; Wang Y; Xia M; Guo Q; Miao X; Wen Z; Xu M; Yin H; Chen H; Chen M; Xiao Y
Aliment Pharmacol Ther; 2022 Jun; 55(12):1524-1533. PubMed ID: 35505467
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A;
Aliment Pharmacol Ther; 2003 Feb; 17(3):333-41. PubMed ID: 12562445
[TBL] [Abstract][Full Text] [Related]
13. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis.
Hatlebakk JG; Berstad A
Aliment Pharmacol Ther; 1997 Apr; 11(2):365-72. PubMed ID: 9146777
[TBL] [Abstract][Full Text] [Related]
14. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Kawamura M; Ohara S; Koike T; Iijima K; Suzuki J; Kayaba S; Noguchi K; Hamada S; Noguchi M; Shimosegawa T;
Aliment Pharmacol Ther; 2003 Apr; 17(7):965-73. PubMed ID: 12656699
[TBL] [Abstract][Full Text] [Related]
15. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis.
Howden CW; Ballard ED; Robieson W
Clin Drug Investig; 2002; 22(2):99-109. PubMed ID: 23315397
[TBL] [Abstract][Full Text] [Related]
16. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Gough AL; Long RG; Cooper BT; Fosters CS; Garrett AD; Langworthy CH
Aliment Pharmacol Ther; 1996 Aug; 10(4):529-39. PubMed ID: 8853756
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole for maintenance of remission of erosive oesophagitis.
Freston JW; Jackson RL; Huang B; Ballard ED
Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
[TBL] [Abstract][Full Text] [Related]
19. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Lauritsen K; Devière J; Bigard MA; Bayerdörffer E; Mózsik G; Murray F; Kristjánsdóttir S; Savarino V; Vetvik K; De Freitas D; Orive V; Rodrigo L; Fried M; Morris J; Schneider H; Eklund S; Larkö A
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():24; discussion 25-7. PubMed ID: 12614304
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]